Physician profile
Haley Young
NPI 1073157582
$5,217.74
in general payments reported to CMS, 2019-2025
35 companies · $75.38 in 2025
The $75.38 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $957 · 2022: $1,691 · 2023: $1,143 · 2024: $1,351 · 2025: $75.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,521 · Education: $48.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,520.69 |
| Education | $48.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $610.69 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $556.76 | 2021-2024 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $546.63 | 2021-2024 | Nucala, Trelegy Ellipta |
| Csl Behring | $510.27 | 2021-2024 | Haegarda, Kcentra, Hizentra |
| Genzyme Corporation | $363.67 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $292.18 | 2021-2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $268.45 | 2021-2024 | Takhzyro, Cuvitru, Eohilia |
| Amgen INC. | $268.40 | 2021-2023 | Tezspire |
| Optinose US, INC. | $227.47 | 2021-2024 | |
| Hospira, INC. | $197.34 | 2023-2024 | |
| Biocryst US Sales Co., LLC | $153.17 | 2021-2024 | Orladeyo |
| Covis Pharma Gmbh | $136.96 | 2021-2022 | |
| Kaleo, INC. | $126.09 | 2022-2024 | Auvi-Q |
| Qol Medical, LLC | $113.08 | 2023-2024 | Sucraid, Sucraid |
| Grifols USA, LLC | $97.78 | 2021-2023 | Xembify, Gamunex-C |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $80.01 | 2023-2024 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.43 | 2021-2022 | |
| Pharming Healthcare, INC. | $68.96 | 2023-2024 | Ruconest |
| Cleerly, INC. | $59.07 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Octapharma USA, INC. | $54.40 | 2024 | Cutaquig |
| Aimmune Therapeutics, INC. | $54.33 | 2022 | |
| Sanofi-Aventis U.S. LLC | $48.99 | 2024 | |
| Nestle Healthcare Nutrition INC. | $42.90 | 2021 | |
| Pfizer INC. | $40.10 | 2021-2022 | |
| Alk-Abello, INC | $37.26 | 2023 | Grastek, Odactra, Ragwitek |
| Phadia US INC. | $31.96 | 2022-2024 | Immunocap |
| Bio Products Laboratory USA, INC. | $27.23 | 2022-2023 | Coagadex, Gammaplex |
| Genentech USA, INC. | $25.64 | 2023 | Xolair |
| Tersera Therapeutics LLC | $18.59 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.74 | 2024 | |
| Lilly USA, LLC | $16.92 | 2021 | |
| Incyte Corporation | $16.33 | 2023 | Opzelura |
| Ibsa Pharma INC. | $16.31 | 2025 | Flector, Licart, Tirosint |
| Teva Pharmaceuticals USA, INC. | $11.47 | 2021 | |
| Biofrontera INC. | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.